Volunteer Donate Get Help

CAR T Therapy for non-Hodgkin's Lymphoma

Published: 2017-12-10 |

Source: University of Pennsylvania School of Medicine

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta. Results from the single-site study, with follow-up extending past two years, will be published today in the New England Journal of Medicine. Both studies were led by Stephen J. Schuster, MD, from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

In the global, multi-center, Novartis-sponsored trial known as JULIET, 38 percent of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the most common form of NHL, who received the investigational treatment had a partial or complete response at three months. About 73 percent of patients who responded remained cancer-free at six months. The trial included 27 sites in 10 countries across North America, Europe, Australia, and Asia. In total 81 patients were infused with CAR T cells and evaluated for a response. At three months, 26 patients (32 percent) achieved a complete response, while five (6 percent) achieved a partial response. The results will be presented today as part of the ASH meeting press program.

©2015 Stephanie Robinson Foundation | Privacy Policy